Study about Predominance of ERG‑Negative High‑Grade Prostate Cancers in African American Men | Chapter 4 | Current Innovations in Medicine and Medical Science Vol. 2

 The most common and well-documented genomic alteration in prostate cancer (CaP), the erythroid transformation-specific associated gene (ERG) fusion, causes altered expression of the ERG oncoprotein. The frequency of ERG is significantly lower in African American (AA) male tumors than in white American (CA) male tumors. Analysis of his ERG alterations at the genomic, transcriptional, and protein levels further suggested a lower frequency of her ERGs in AA-Cap compared with CA-Cap. Based on  preliminary results, this study focused on the increased association between ERG-negative status and high-grade prostate tumors in AA men. Representative whole-body prostate sections from a matched cohort of 63 AA and 63 CA men with Gleason scores of 4+3 and  8-10 were immunohistochemically analyzed for ERG oncoprotein. Analyzed. The striking finding of this study was that ERG expression was 3 times more likely to be present in the higher-grade index tumors of CA men compared to AA men (31 of 63 vs. 10 of 63 patients, respectively; P<0.0001). Even though the mechanisms underlying such disparities have not been identified, the current study, along with our previous findings, suggests that ERG typing may improve understanding of ethnic differences and future CaP targeted therapy.

Author(s) Details:

James Farrell,
Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD-20814, USA and Department of Urology, Walter Reed National Military Medical Center, Bethesda, MD-20889, USA.

Gavin Yetter,
Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD-20814, USA and Department of Chemistry, United States Naval Academy, Annapolis, MD-21402, USA.

Indu Kohaar,
Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD-20814, USA.

Denise Young,
Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD-20814, USA.

Yongmei Chen,
Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD-20814, USA.

Jennifer Cullen,
Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD-20814, USA.

Inger L. Rosner,
Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD-20814, USA and Department of Urology, Walter Reed National Military Medical Center, Bethesda, MD-20889, USA.

Jacob Kagan,
Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Sudhir Srivastava,
Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

David G. McLeod,
Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD-20814, USA and  Department of Urology, Walter Reed National Military Medical Center, Bethesda, MD-20889, USA.

Isabell A. Sesterhenn,
Department of Genitourinary Pathology, Joint Pathology Center, Silver Spring, MD-20910 1290, USA.

Shiv Srivastava,
Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD-20814, USA.

Gyorgy Petrovics,
Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD-20814, USA.

Please see the link here: https://stm.bookpi.org/CIMMS-V2/article/view/8217